Myeloproliferative Neoplasms (MPN)
Symptoms, Doctors, Treatments, Advances & More

Myeloproliferative Neoplasms (MPN) Overview

Save information for later
Sign Up

Learn About Myeloproliferative Neoplasms (MPN)

What is the definition of Myeloproliferative Neoplasms (MPN)?
Myeloproliferative neoplasms are rare blood cancers caused by the body making too many red blood cells, white blood cells, or platelets. There are several types of myeloproliferative neoplasms, including chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia.
What are the symptoms of Myeloproliferative Neoplasms (MPN)?
Symptoms of myeloproliferative neoplasms may not appear for years. Symptoms of myeloproliferative neoplasms depend on the type. The most common symptom is discomfort or pressure on the left side below the ribs due to an enlarged spleen. Other symptoms may include bone pain; night sweats; fever; fatigue; bruising easily; loss of appetite; unexplained weight loss; unexplained bleeding; blood in the urine; headaches; dizziness; blurred or double vision; pale or itchy skin; abdominal fullness; reddened face; weakness; shortness of breath; hearing problems; cough; swelling of the face, throat, hands or feet; muscle pain; and diarrhea.
Not sure about your diagnosis?
Check Your Symptoms
What are the different types of Myeloproliferative Neoplasms (MPN)?

Common conditions include: Myelofibrosis

What are the current treatments for Myeloproliferative Neoplasms (MPN)?
There is currently no cure for myeloproliferative neoplasms. Treatment for myeloproliferative neoplasms is focused on relieving the symptoms and preventing complications. Treatments for myeloproliferative neoplasms include watchful waiting, phlebotomy, platelet apheresis, transfusion therapy, chemotherapy, radiation therapy, drug therapy, immunotherapy, targeted therapy, chemotherapy, and stem cell transplant.
Who are the top Myeloproliferative Neoplasms (MPN) Local Doctors?
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Ruben A. Mesa
Hematology | Oncology
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Ruben A. Mesa
Hematology | Oncology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mesa is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is board certified in American Board Of Internal Medicine, Hematology. Dr. Mesa is currently accepting new patients.

Elite in Myeloproliferative Neoplasms (MPN)
Dr. Brady Stein
Hematology
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Brady Stein
Hematology
233 E Superior St 1st Fl, Olson Pavilion, 
Chicago, IL 
866-587-4322
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brady Stein is a Hematologist practicing medicine in Chicago, Illinois. Dr. Stein is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Essential Thrombocythemia. Dr. Stein is board certified in American Board Of Internal Medicine - Hematology (Certified).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Aaron Gerds
Hematology Oncology | Hematology | Oncology
Elite in Myeloproliferative Neoplasms (MPN)
Dr. Aaron Gerds
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
866-223-8100
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aaron Gerds is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 24 years. Dr. Gerds is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Gerds is board certified in American Board Of Internal Medicine, 2013.

View All Doctors
What are the latest Myeloproliferative Neoplasms (MPN) Clinical Trials?
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.

View All Clinical Trials